learndrugs
Renal / Genitourinary

Polycystic Kidney Disease

PKD High-yield Verified · Sep 2026

Polycystic kidney disease is an inherited disorder in which many fluid-filled cysts grow in both kidneys, enlarging them and gradually destroying kidney function.

For the nurse, ADPKD means guarding the kidneys for decades: home blood pressure, water spread through the day, sodium limits and no routine NSAIDs. It also means knowing two emergencies — a thunderclap headache and liver injury on tolvaptan.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 One inherited gene, then a "second hit"

[ADPKD] What it is. "Polycystic kidney disease (PKD) is a genetic disorder that causes many fluid-filled cysts to grow in your kidneys. Unlike the usually harmless simple kidney cysts that can form in the kidneys later in life, PKD cysts can change the shape of your kidneys, including making them much larger." It "affects 1 in every 400 to 1,000 people and is the most common kidney disorder passed down through family members" (NIDDK), and it is "the most common genetic cause of renal failure worldwide" (StatPearls).

Autosomal dominant: one parent is enough. "“Autosomal dominant” means you can get the PKD gene mutation, or defect, from only one parent." KDIGO 2025: "Thus, children and siblings of people with ADPKD are normally at a 50% risk of also having ADPKD." StatPearls: "PKD1 (chromosome 16p13.3) accounts for 85% of ADPKD cases, and PKD2 (4q21) contributes 15%," and "People with PKD1 also usually progress more quickly to kidney failure than people with PKD2" (NIDDK). Not every case is inherited: StatPearls reports that "10% to 15% of patients with ADPKD have no known family history," while MedlinePlus Genetics puts new mutations at about 10 percent.

The second hit. "Each renal cyst is believed to originate from a single, genetically transformed clonal hyperproliferative epithelial cell" — a somatic "second hit" in the PKD1 or PKD2 gene then "leads to cyst growth and development." Signs usually appear in adulthood: providers "usually diagnose ADPKD between the ages of 30 and 50, when signs and symptoms start to appear." [ARPKD] The recessive form is different — "very rare," it "usually presents in childhood and often causes death in childhood or perinatally."

A single inherited variant plus a second hit in one tubule cell starts each cyst; decades of cyst growth enlarge the kidneys, raise blood pressure and eventually cause kidney failure.

02 cAMP drives the cysts — and vasopressin drives cAMP

Polycystins and cAMP. The two proteins "play a crucial role in cell proliferation, differentiation, and fluid secretion through G protein-mediated or JAK-STAT-mediated signaling pathways, which results in increased intracellular concentrations of cyclic adenosine monophosphate (cAMP), leading to an increase in chloride secretion across the luminal membrane." "Chloride-rich fluid secretion is an essential component of cystogenesis, leading to the expansion of cysts, even after the detachment from their parent nephron."

Why water and tolvaptan help. Vasopressin acting at the V2 receptor raises cAMP. StatPearls: "Patients are instructed to drink three liters of fluids daily to suppress vasopressin, thereby decreasing cAMP production and inhibiting cyst production," and "Tolvaptan slows the progression of autosomal dominant polycystic kidney disease by blocking the reception of vasopressin signaling at the V2 receptor, lowering the intracellular cyclic AMP that would otherwise stimulate cystic proliferation and growth."

Kidney function holds, then falls. "Renal function can remain normal for decades. However, once the glomerular filtration rate (GFR) starts to decline, renal impairment is usually rapid, with an average GFR loss of 4.0 to 5.0 mL/minute/year." "Total kidney volume is the primary predictive biomarker of future GFR loss."

Vasopressin acting at the V2 receptor raises cAMP, which drives cyst-cell proliferation and fluid secretion; drinking water suppresses vasopressin, and tolvaptan blocks the receptor.

03 Cysts squeeze vessels, bleed, get infected — and the brain is at risk

Hypertension first. "The continuous expansion of cysts compresses renal vessels, leading to intrarenal ischemia, which activates the renin-angiotensin-aldosterone system as well as other factors." "Hypertension is the most universal and earliest clinical presentation in most patients with ADPKD."

Pain, bleeding, infection, stones. "Episodes of acute flank pain are often seen due to cyst bleeding, infection, stones, and, rarely, tumors." "Cyst hemorrhage is a frequent complication causing gross hematuria when the cyst communicates with the collecting system." "Renal stone disease occurs in about 20% to 25% of patients with ADPKD" (StatPearls).

Outside the kidney. Liver cysts "are a common manifestation of ADPKD and are more prevalent in women," growing with "high estrogen states such as pregnancy and oral contraceptive use." "A ruptured cerebral aneurysm is the most serious extrarenal complication of ADPKD and has a four times higher prevalence in ADPKD patients compared to the general population." Mitral valve prolapse, diverticulosis and hernias also occur.

Cyst growth raises blood pressure through renal ischemia and causes bleeding, infection and stones; aneurysm rupture is the most serious extrarenal complication.

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

[ADPKD] Autosomal dominant inheritance — a PKD1 or PKD2 variant from one parent; children and siblings of a person with ADPKD "are normally at a 50% risk of also having ADPKD" (KDIGO 2025) New (spontaneous) mutation — StatPearls: 10% to 15% have no known family history; MedlinePlus Genetics: about 10 percent of cases PKD1 vs PKD2 — PKD1 (about 85%) progresses to kidney failure faster; PKD2 disease is milder, with later hypertension (StatPearls) Uncontrolled blood pressure — speeds kidney damage and is a modifiable factor for aneurysm development and rupture (KDIGO) modifiable Smoking and excess alcohol — modifiable aneurysm risk factors (StatPearls); smoking also raises blood pressure (NIDDK) modifiable Estrogen (pregnancy, oral contraceptives) — liver cysts grow in high-estrogen states (StatPearls)

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

No symptoms for years early Expected
Why: "In many cases, ADPKD doesn’t cause signs or symptoms until cysts are a half inch or larger in size" (NIDDK). Kidney function "can remain normal for decades."
High blood pressure early Hold & notify
Why: Renal ischemia from expanding cysts activates the renin-angiotensin-aldosterone system; hypertension is "the most universal and earliest clinical presentation."
Chronic pain in the back and sides Expected
Why: "The most common symptoms are pain in the back and sides, between the ribs and hips, and headaches." Pain is "usually due to kidney or liver cysts" — cyst growth stretching tissue, bleeding, infection or stones (NIDDK).
A severe headache, one that feels different from usual, or one that will not go away Hold & notify
Why: NIDDK: brain aneurysms "might cause headaches that are severe or feel different from other headaches. See a health care provider even before you take over-the-counter pain medicines for severe headaches or headaches that won’t go away." A sudden thunderclap headache is the emergency below.
Blood in the urine (hematuria) Hold & notify
Why: A cyst that bleeds into the collecting system causes gross hematuria. NIDDK tells patients: "If you have hematuria, see a health care provider right away." KDIGO: gross hematuria from cyst rupture "generally resolves within 2–7 days with conservative therapy."
Fever with acute flank or abdominal pain Hold & notify
Why: Possible kidney cyst infection. KDIGO: people "who present with fever, acute abdominal or flank pain, and increased white blood cells and/or C-reactive protein (CRP) should be worked up for kidney cyst infection." StatPearls: "Cyst and urinary tract infections require immediate treatment to prevent retrograde seeding of the renal parenchyma."
Enlarged kidneys; abdominal fullness; liver cysts
Why: Cysts "can change the shape of your kidneys, including making them much larger." Liver cysts are more common in women and "rarely cause hepatic function impairment."
Sudden, severe "worst headache in my life" peaking within a minute, with vomiting, seizure or altered consciousness late Report immediately
Why: Possible ruptured intracranial aneurysm (subarachnoid hemorrhage). KDIGO: "Recognition of such symptoms should prompt immediate medical attention," with evaluation in an emergency department. NIDDK: "Large brain aneurysms are life threatening and need immediate medical treatment."
Rising creatinine, fatigue, signs of kidney failure late Hold & notify
Why: "More than half of people with ADPKD progress to kidney failure by age 70" (NIDDK).

Diagnostics

Test In this disorder Normal
Kidney ultrasound (first imaging test) NIDDK: "Health care providers diagnose ADPKD using imaging tests and genetic testing. A health care provider can make a diagnosis based on these tests and your age, family history of PKD, and how many cysts you have." KDIGO: "For screening adults at risk of ADPKD, we recommend first using abdominal imaging." Multiple cysts in both kidneys, interpreted with age and family history NIDDK / KDIGO 2025 —
MRI — total kidney volume; Mayo Imaging Classification "Total kidney volume is the primary predictive biomarker of future GFR loss" (StatPearls). KDIGO: "We recommend employing the Mayo Imaging Classification (MIC) to predict future" kidney function decline. Kidney and cyst size tracked over time; larger kidneys for age predict faster decline —
Genetic testing and counseling KDIGO: "Genetic testing can diagnose ADPKD in people with or without a known family history." NIDDK suggests talking "with a genetics counselor as part of your health care team." PKD1 or PKD2 variant —
Home and office blood pressure KDIGO suggests out-of-office measurement with home BP monitoring for people with ADPKD. The older NIDDK page (2017) gives a single goal — "Aim for a blood pressure goal of less than 120/80" — and is superseded by the age-stratified KDIGO 2025 targets. KDIGO target for ages 18–49 (CKD G1–G2, BP above 130/85 mm Hg): 110/75 mm Hg or lower by home BP monitoring, "if tolerated"; age 50 and older: "a target mean systolic blood pressure (SBP) of <120 mm Hg, if tolerated," by standardized office measurement KDIGO 2025 —
Suspected cyst infection — urine and blood cultures KDIGO: "A urine culture should be obtained before antibiotics are started for UTI, especially for upper UTI and/or suspected kidney cyst infection. Blood cultures should be obtained if an upper UTI or kidney cyst infection is suspected." Fever above 38 °C (100.4 °F), flank pain, raised white count or CRP —
Unenhanced CT (stones) "Unenhanced CT scans of the abdomen and pelvis are the most helpful for diagnosing nephrolithiasis in ADPKD patients." "Most stones are composed of uric acid, calcium oxalate, or both." Uric acid and/or calcium oxalate stones —
Aneurysm screening — time-of-flight MRA (selected patients) KDIGO: "We recommend screening for ICA in people with ADPKD and a personal history of SAH or a positive family history of ICA, SAH, or unexplained sudden death in those eligible for treatment and who have a reasonable life expectancy (1D)," using "Time-of-flight magnetic resonance angiography (MRA) without gadolinium enhancement." Offered to those with a personal history of subarachnoid hemorrhage or a family history of aneurysm, SAH or unexplained sudden death KDIGO 2025 —
Tolvaptan liver tests (ALT, AST, bilirubin) Boxed warning: "Measure ALT, AST and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter." Normal before and throughout treatment JYNARQUE label —

Complications

Warning: Ruptured intracranial aneurysm (subarachnoid hemorrhage) Report immediately
"A ruptured cerebral aneurysm is the most serious extrarenal complication of ADPKD." KDIGO: "All people with ADPKD should be educated to recognize thunderclap headache, characterized by a severe sudden-onset headache that reaches its maximum intensity within seconds to a minute."
KDIGO recommends informing every adult with ADPKD about the risk, and screening selected patients. Risk rises "with a personal or family history of cerebral aneurysm or subarachnoid hemorrhage, female sex, and older age," and "Smoking, hypertension, and excess alcohol intake are modifiable risk factors." See Subarachnoid Hemorrhage & Cerebral Aneurysm.
Black-box warning — most severe: ■ [TOL] Tolvaptan — serious and potentially fatal liver injury Report immediately
"JYNARQUE (tolvaptan) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported." It is available only through a REMS program.
Patients are told to "immediately stop taking JYNARQUE and notify their healthcare provider if they have symptoms or signs (e.g., abnormal transaminase elevations) of hepatic injury (such as fatigue, anorexia, nausea, right upper abdominal discomfort or tenderness, vomiting, fever, rash, pruritus, icterus, dark urine or jaundice)."
Warning: Cyst hemorrhage Hold & notify
"Cyst hemorrhage episodes are usually self-limited, and patients respond well to conservative management with bed rest, analgesics, and increased fluid intake to prevent clots from obstructing the upper urinary tract."
"Rarely, bleeding is more severe, leading to hemodynamic instability, which would require hospitalization, transfusions, and supportive care." Occasionally a hemorrhagic cyst ruptures into the retroperitoneum. Treat hemodynamic instability as an emergency; otherwise report and follow the conservative plan.
Warning: Kidney cyst infection and UTI Hold & notify
"Urinary tract infections (UTIs) are common in ADPKD," including "cystitis, acute pyelonephritis, cyst infection, and perinephric abscesses."
KDIGO suggests "4–6 weeks of antibiotic therapy rather than a shorter course (2D)" for kidney cyst infection, with "A lipid-soluble antibiotic (e.g., fluoroquinolones, trimethoprim-sulfamethoxazole)" if possible.
Caution: Kidney failure
"End-stage kidney disease requiring dialysis or renal transplantation is the most common complication of ADPKD." "People with kidney failure must have dialysis or a kidney transplant to replace their kidney function."
KDIGO: "Kidney transplantation is the preferred treatment for kidney failure in people with ADPKD." NIDDK: "More than half of people with ADPKD progress to kidney failure by age 70"; StatPearls gives "about half and possibly as many as three-quarters" by 70.
Caution: Pregnancy
NIDDK: "Although most women with PKD have normal pregnancies, women with PKD who have high blood pressure and decreased kidney function are more likely to have preeclampsia."
KDIGO: "Women with ADPKD are at an increased risk of preeclampsia and preterm delivery and should be monitored carefully throughout their pregnancy and in the postpartum period." Tolvaptan is stopped before pregnancy.

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

ACE Inhibitors First-line
Cardiovascular · lisinopril

First-line for hypertension in ADPKD. KDIGO: "For people with ADPKD and high BP, we recommend using renin-angiotensin system inhibitors (RASi) (angiotensin-converting enzyme inhibitor [ACEi] or angiotensin II receptor blocker [ARB]) as first-line treatment to achieve the recommended target BP (1C)." Never combined: "We recommend avoiding any combination of ACEi, ARB, and direct renin inhibitor (DRI) therapy in patients with ADPKD, with or without diabetes (1B)."
ARBs First-line
Cardiovascular · losartan

First-line alternative to an ACE inhibitor under the same KDIGO recommendation — one RAS inhibitor, never an ACEi–ARB combination.
NSAIDs
Musculoskeletal · ibuprofen

Avoid for chronic pain. KDIGO: "Acetaminophen is the first-line drug for chronic pain control. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is discouraged for treatment of chronic pain, but these may be used short-term for acute pain in people with stable kidney function." StatPearls lists "avoidance of NSAIDs" among the lifestyle measures; NIDDK warns that "Sometimes AKI is caused by using OTC painkillers for a long time."
Opioid Analgesics High-alert
Nervous · morphine

Last line for chronic kidney pain. KDIGO puts nonpharmacologic measures and acetaminophen first; "Opioid use should be limited" to people who do not respond to earlier steps.

Beyond medications

  • Water spread through the day — KDIGO suggests "adapting water intake, spread throughout the day, to achieve at least 2–3 liters of water intake per day in people with ADPKD and an eGFR" of 30 or more without contraindications (2D). "People with CKD G4–G5 (eGFR <30 ml/min per 1.73 m2) or who have a clinical contraindication to high water intake should drink to thirst and/or follow individualized clinical advice."
  • Sodium under 2 g a day — "All ADPKD patients are advised to limit their sodium intake to less than 2 grams per day" (StatPearls). KDIGO: "People with ADPKD should be counseled against adding salt to their food, and to avoid processed foods (typically high in sodium) as much as possible."
  • No routine protein restriction — KDIGO notes that no benefit of protein restriction has been demonstrated; NIDDK advises "high-quality protein and smaller portions of protein."
  • Tolvaptan (JYNARQUE), for selected patients — "indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)." Dispensed only through a REMS program because of liver injury; causes marked thirst and urination. No doses on this page.
  • Stop smoking; stay active; keep a healthy weight — "Be active for 30 minutes or more on most days." "Lose weight. Being overweight makes your kidneys work harder." "Quit smoking. Cigarette smoking can raise your blood pressure, making your kidney damage worse" (NIDDK).
  • Protect enlarged kidneys — "Trauma to your body, especially to your back and sides, may cause kidney cysts to burst"; people who play contact sports may need an MRI to judge whether the sport is safe (NIDDK).
  • What does not slow ADPKD — KDIGO recommends or suggests against mTOR inhibitors, statins, metformin and somatostatin analogues for slowing kidney disease, and SGLT2 inhibitors should not be used to slow eGFR decline in ADPKD.
  • Kidney failure — dialysis or transplantation; "Kidney transplantation is the preferred treatment for kidney failure in people with ADPKD."

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment
Check blood pressure at every contact and review the patient's home BP log against the KDIGO target for their age.
Why: Hypertension is the earliest and most universal finding, and uncontrolled BP both speeds kidney damage and is "a moderate modifiable factor for ICA development and rupture."
Ask about flank or back pain, blood in the urine, fever and urinary symptoms, and what the patient takes for pain.
Why: Acute flank pain comes from "cyst bleeding, infection, stones, and, rarely, tumors"; long-term OTC painkillers can cause acute kidney injury.
Ask every patient about headaches — especially any sudden, severe headache — and about a family history of aneurysm or sudden death.
Why: KDIGO: "All people with ADPKD should be educated to recognize thunderclap headache"; a family history of ICA, SAH or unexplained sudden death is a screening indication.
On tolvaptan, confirm liver tests are on schedule and ask about fatigue, nausea, right upper abdominal discomfort, itching, dark urine or yellow skin.
Why: Boxed warning: "serious and potentially fatal liver injury"; ALT, AST and bilirubin are measured at 2 and 4 weeks, monthly for 18 months, then every 3 months.
On tolvaptan, watch for dehydration — weight loss, tachycardia, hypotension, dizziness, confusion.
Why: Label: "Monitor for weight loss, tachycardia and hypotension because they may signal dehydration."
Interventions
Escalate at once for a sudden, severe headache that peaks within a minute, especially with vomiting, seizure or altered consciousness.
Why: KDIGO: "Recognition of such symptoms should prompt immediate medical attention," with evaluation in an emergency department.
For fever with flank pain, obtain urine (and blood) cultures before antibiotics as ordered, and report promptly.
Why: KDIGO: "A urine culture should be obtained before antibiotics are started"; cyst infections "require immediate treatment to prevent retrograde seeding of the renal parenchyma" (StatPearls).
For cyst bleeding, support bed rest, analgesia without NSAIDs and fluids as ordered; escalate at once for falling blood pressure, rising heart rate or other signs of hemodynamic instability.
Why: Most bleeds settle with conservative care; "Rarely, bleeding is more severe, leading to hemodynamic instability, which would require hospitalization, transfusions, and supportive care."
Question an order for a long-term NSAID for chronic kidney pain; expect acetaminophen first.
Why: KDIGO: "Acetaminophen is the first-line drug for chronic pain control," and NSAIDs are "discouraged for treatment of chronic pain."
Hold tolvaptan and notify the provider if the patient cannot drink enough water — vomiting, diarrhea, no access to water, or inability to sense thirst.
Why: Label: in those situations "they should stop taking JYNARQUE and inform their health care provider right away"; KDIGO calls for a "sick-day plan."
Patient and family teaching
Teach the thunderclap headache warning: the "worst headache in my life," reaching full strength within 60 seconds — call for emergency care.
Why: KDIGO Figure 38 tells patients to "Seek immediate medical attention" and "Have evaluation in an emergency department."
Drink water spread through the day (KDIGO: at least 2–3 liters a day if kidney function allows), limit sodium to under 2 g a day, and avoid adding salt and processed foods.
Why: Water suppresses vasopressin and cAMP-driven cyst growth; sodium restriction supports blood-pressure control.
Report blood in the urine promptly.
Why: NIDDK: "If you have hematuria, see a health care provider right away." KDIGO advises discussing gross hematuria at diagnosis "to avoid unnecessary worry if it happens."
On tolvaptan: drink when thirsty and through the day and night if awake; stop the drug and call for liver-injury symptoms, and stop and call if you cannot keep up with fluids.
Why: Label: "Instruct patients to drink water when thirsty, and throughout the day and night if awake." Thirst, polyuria and nocturia are the most common effects. Also avoid grapefruit juice.
Offer genetic counseling to patients planning a family, and explain the inheritance risk to relatives.
Why: Children and siblings of people with ADPKD "are normally at a 50% risk of also having ADPKD" (KDIGO).
Stop smoking, limit alcohol, keep active, and protect the back and sides from blows.
Why: Smoking and hypertension are modifiable aneurysm risks; trauma "may cause kidney cysts to burst."

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    Fatigue, nausea, right upper abdominal tenderness, dark urine and yellow sclerae in a patient on tolvaptan. Also: NSAID use for kidney pain.

  2. 2
    Analyze cues

    These are the label's named signs of hepatic injury, and tolvaptan "can cause serious and potentially fatal liver injury." The NSAID use is a separate problem — "discouraged for treatment of chronic pain" in ADPKD.

  3. 3
    Prioritize

    Possible drug-induced liver injury is the emergency. Tolvaptan must stop now; liver tests are needed urgently.

  4. 4
    Generate solutions

    Tell her to take no further tolvaptan doses, notify the provider immediately, and anticipate ALT, AST and bilirubin today. Address the ibuprofen: switch to the acetaminophen-first plan the provider orders.

  5. 5
    Take action

    SBAR: 38-year-old with ADPKD on tolvaptan for 10 weeks; 5 days of fatigue and nausea, RUQ tenderness, dark urine, scleral icterus. Last LFTs normal 4 weeks ago. Tolvaptan held — requesting immediate evaluation and liver tests.

  6. 6
    Evaluate

    Follow the liver tests; the label says to "immediately discontinue JYNARQUE, obtain repeat tests as soon as possible (within 48 to 72 hours), and continue testing as appropriate." Re-teach the stop-and-call symptom list and the NSAID rule.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Nephrology clinic · 1000

A 38-year-old woman with ADPKD (her mother had kidney failure) started tolvaptan 10 weeks ago because her kidneys are enlarging quickly. She also takes an ACE inhibitor and measures her blood pressure at home.

Today — BP 126/82 at home this week; T 37.0 °C; HR 86
History — tired and nauseated for about 5 days, with an ache under the right ribs; says her urine looks darker
Exam — tender right upper abdomen; sclerae slightly yellow
Medicines — tolvaptan (REMS), ACE inhibitor; took ibuprofen twice this week for flank pain
Last labs — liver tests normal 4 weeks ago
Q1 Multiple choice
A patient on tolvaptan reports 5 days of fatigue, nausea, right upper abdominal discomfort and dark urine. What should the nurse do first?
  1. A. Encourage more water intake and recheck in a week
  2. B. Tell the patient to stop tolvaptan and notify the provider immediately
  3. C. Reduce the tolvaptan dose by half
  4. D. Give an antiemetic and continue the medication
Reveal answer & rationale
Answer: B
Label: "immediately stop taking JYNARQUE and notify their healthcare provider if they have symptoms or signs … of hepatic injury" (B). Water (A) treats aquaresis, not liver injury; dose changes (C) and continuing (D) ignore a boxed warning for "potentially fatal liver injury."
Q2 Select all that apply
Which findings in a patient with ADPKD require emergency care? Select all that apply.
  1. A. A sudden, severe headache that reached full strength within a minute
  2. B. Jaundice and dark urine while taking tolvaptan
  3. C. Thirst and waking at night to urinate while taking tolvaptan
  4. D. Heavy flank bleeding with falling blood pressure and a rising heart rate
  5. E. A mild ache in the back and sides that has been present for months
Reveal answer & rationale
Answer: A, B, D
Thunderclap headache "should prompt immediate medical attention" (A). Tolvaptan liver injury can be fatal (B). Bleeding with hemodynamic instability requires hospitalization and transfusion (D). Thirst, polyuria and nocturia are the most common expected effects of tolvaptan (C), and chronic back and flank pain is common in ADPKD (E).
Q3 Multiple choice
Which diet and fluid instruction fits KDIGO 2025 for a patient with ADPKD and an eGFR of 70?
  1. A. Restrict fluids to 1 liter a day to protect the kidneys
  2. B. Drink water spread through the day, aiming for at least 2–3 liters, and keep sodium under about 2 g a day
  3. C. Follow a very-low-protein diet to slow cyst growth
  4. D. Drink water only with meals
Reveal answer & rationale
Answer: B
KDIGO suggests water "spread throughout the day, to achieve at least 2–3 liters of water intake per day" when eGFR is 30 or more, and sodium under 2 g a day (B). Fluid restriction (A) and drinking only with meals (D) do not suppress vasopressin across the day; no benefit of protein restriction has been shown (C).
Q4 Multiple choice
A patient with ADPKD asks for ibuprofen for chronic flank pain. What does the nurse expect instead?
  1. A. An opioid as the first choice
  2. B. Acetaminophen as the first-line drug, after nonpharmacologic measures
  3. C. Daily aspirin
  4. D. Ibuprofen is preferred because it reduces cyst growth
Reveal answer & rationale
Answer: B
KDIGO: "Acetaminophen is the first-line drug for chronic pain control," and NSAIDs are "discouraged for treatment of chronic pain" (B); nonpharmacologic measures come first. Opioids are last line — "Opioid use should be limited" (A). Aspirin (C) is not the KDIGO pain choice, and NSAIDs do not slow cysts (D).
Q5 Multiple choice
Which statement about how ADPKD is inherited is correct?
  1. A. Both parents must carry the gene
  2. B. Each child of an affected parent has about a 50% risk
  3. C. Only boys can be affected
  4. D. It is never caused by a new mutation
Reveal answer & rationale
Answer: B
It is autosomal dominant — "you can get the PKD gene mutation, or defect, from only one parent," and children "are normally at a 50% risk" (B). Both parents are needed only in the recessive form (A); both sexes are affected (C); some cases arise from new mutations (D).

Common questions

What causes polycystic kidney disease?
Common causes and risk factors include [adpkd] autosomal dominant inheritance — a pkd1 or pkd2 variant from one parent; children and siblings of a person with adpkd "are normally at a 50% risk of also having adpkd" (kdigo 2025), new (spontaneous) mutation — statpearls: 10% to 15% have no known family history; medlineplus genetics: about 10 percent of cases, pkd1 vs pkd2 — pkd1 (about 85%) progresses to kidney failure faster; pkd2 disease is milder, with later hypertension (statpearls), uncontrolled blood pressure — speeds kidney damage and is a modifiable factor for aneurysm development and rupture (kdigo), smoking and excess alcohol — modifiable aneurysm risk factors (statpearls); smoking also raises blood pressure (niddk), and others.
Why is drinking so much water recommended?
Vasopressin raises cAMP, which drives cyst growth. Drinking water suppresses vasopressin: StatPearls explains that patients drink "to suppress vasopressin, thereby decreasing cAMP production and inhibiting cyst production," and KDIGO 2025 suggests at least 2–3 liters a day, spread through the day, when kidney function allows. People with advanced CKD drink to thirst instead.
Does PKD cause kidney cancer?
No clear link has been found. NIDDK: "Researchers have not found a link between PKD and kidney cancer," and KDIGO: "There is no clear association between ADPKD and an increased risk of renal cell carcinoma (RCC)."
Who takes tolvaptan?
Adults "at risk of rapidly progressing" ADPKD — not everyone with PKD. It blocks the vasopressin V2 receptor, causes marked thirst and urination, carries a boxed warning for "serious and potentially fatal liver injury," and is available only through a REMS program.
Is every relative of a person with ADPKD screened for brain aneurysms?
No. KDIGO recommends informing everyone with ADPKD about the risk, and screening people with a personal history of subarachnoid hemorrhage or a family history of aneurysm, SAH or unexplained sudden death, using MRA without gadolinium.
Is there a cure?
Not yet. NIDDK: "Although a cure doesn’t exist yet for ADPKD, treatment can help reduce your complications, which can help you live longer." For kidney failure, "Kidney transplantation is the preferred treatment."

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.